Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399222 | 1.00 | HCAR2 (0.55) | HCAR2SMYD3MKNK1MKNK2CHRNB4 | |
| SCHEMBL14395549 | 0.79 | HCAR2 (0.52) | HCAR2SMYD3MKNK1MKNK2 | |
| SCHEMBL14755489 | 0.79 | HCAR2 (0.52) | HCAR2SMYD3MKNK1MKNK2CHRNB4 | |
| SCHEMBL4392022 | 0.77 | HCAR2 (0.53) | HCAR2 | |
| SCHEMBL4392027 | 0.77 | HCAR2 (0.53) | HCAR2 | |
| SCHEMBL14183649 | 0.77 | TPMT (0.44) | — | |
| SCHEMBL15635597 | 0.77 | TPMT (0.44) | — | |
| SCHEMBL12818742 | 0.77 | TPMT (0.44) | — | |
| SCHEMBL4196968 | 0.76 | HCAR2 (0.69) | HCAR2SMYD3MKNK1MKNK2PKM | |
| SCHEMBL28835397 | 0.75 | HCAR2 (0.57) | HCAR2MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383658-B2 | Isoxazole based neuronal nicotinic receptor ligands and methods of use | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20090306096-A1 | Novel Isoxazoles and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306096-A1 | Novel Isoxazoles and Methods of Use Thereof | XDH, PRDX5, CYP4X1 | HCAR2 672/4885SMYD3 3778/4885MKNK1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.